Last reviewed · How we verify
NCT06620042
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression
Phase 2 trial testing Ketamine in Bipolar Depression in 20 participants. Completed in 31 October 2025.
31 October 2025
Quick facts
| Lead sponsor | Brian Barnett |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 20 |
| Start date | 12 November 2024 |
| Primary completion | 31 October 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Ketamine (ketamine) — full drug profile →
- Functional magnetic resonance imaging (fMRI)
Conditions studied
- Bipolar Depression — all drugs for Bipolar Depression →
- Treatment Resistant Bipolar Depression — all drugs for Treatment Resistant Bipolar Depression →
Sponsor
Brian Barnett
Who can join
Adults 18 to 75, any sex, with Bipolar Depression or Treatment Resistant Bipolar Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective open-label observational study of patients with treatment resistant bipolar depression referred for intravenous ketamine, with an interventional component of fMRI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06620042
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ketamine
Trials testing the same drug.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT06963294 — Ketamine and Dexmedetomidine for Delirium in Joint Arthroplasty · NA · not yet recruiting
- NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07197684 — Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surg · NA · not yet recruiting
- NCT06231563 — Ketamine for Veterans With Parkinson's Disease · Phase 2 · recruiting
Other recruiting trials for Bipolar Depression
Currently open trials in the same condition.
- NCT07266545 — RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) · Phase 4 · recruiting
- NCT07246044 — HD-tDCS for Adolescent Bipolar Depression Targeting S1 · NA · recruiting
- NCT07121894 — Ketogenic Intervention for Bipolar Depression · NA · recruiting
- NCT07108257 — Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression · NA · recruiting
- NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06620042 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brian Barnett
- Last refreshed: 10 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06620042.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing